信迪利单抗对比多西他赛作为中国晚期或转移性鳞状非小细胞肺癌患者二线治疗的成本效果分析

数据集获取（Figshare）

• 源站标题：Economic evaluation of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer in China: a model-based cost-effectiveness analysis
• DOI：10.6084/m9.figshare.24288062.v1
• 发布日期：2023-10-11
• 文件数：2 个
• 文件总体积：1.72 MB
• 源站页面：https://tandf.figshare.com/articles/dataset/Economic_evaluation_of_sintilimab_versus_docetaxel_as_second-line_treatment_for_patients_with_advanced_or_metastatic_squamous_non-small-cell_lung_cancer_in_China_a_model-based_cost-effectiveness_analysis/24288062

命令行下载

curl -L -o "ierp_a_2267177_sm8117.docx" "https://ndownloader.figshare.com/files/42633227"
curl -L -o "ierp_a_2267177_sm7520.docx" "https://ndownloader.figshare.com/files/42633230"

文件清单

• ierp_a_2267177_sm8117.docx（17.38 KB）
• ierp_a_2267177_sm7520.docx（1.70 MB）

文件总体积 1.72 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

The current study aimed to evaluate the cost-effectiveness of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in China.
A partitioned survival model was established to track 3-week patients’ transition and project the health and economic outputs in 15-year horizon of the two competing options among sintilimab and docetaxel. Clinical data were obtained from the ORIENT-3 trial, and cost and utility values were gathered from the local charges and published studies. Total costs, life-years, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) were evaluated. Sensitivity analyses were conducted to assess the robustness of the model outcomes.
Base-case results revealed that sintilimab yield marginal cost of $4,700.53 and additional 0.32 QALYs, resulting in an ICER of $14,615.31 per QALY gained, which is lower than the willingness-to-pay threshold of $38,224/QALY in China. One-way sensitivity analyses showed that the cost of best supportive care was the main driver of the ICER, and probabilistic sensitivity analyses demonstrated that the model outputs were robust.
Sintilimab could be considered the cost-effective second-line strategy for patients with advanced or metastatic squamous NSCLC compared with docetaxel in China.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.24288062.v1（source: https://tandf.figshare.com/articles/dataset/Economic_evaluation_of_sintilimab_versus_docetaxel_as_second-line_treatment_for_patients_with_advanced_or_metastatic_squamous_non-small-cell_lung_cancer_in_China_a_model-based_cost-effectiveness_analysis/24288062）。